Cargando…
Will we cure cancer by sequencing thousands of genomes?
The promise to understand cancer and develop efficacious therapies by sequencing thousands of cancers has not occurred. Mutations in specific genes termed oncogenes and tumor suppressor genes are extremely heterogeneous amongst the same type of cancer as well as between cancers. They provide little...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906905/ https://www.ncbi.nlm.nih.gov/pubmed/24330806 http://dx.doi.org/10.1186/1755-8166-6-57 |
| _version_ | 1782301540548083712 |
|---|---|
| author | Nicholson, Joshua M |
| author_facet | Nicholson, Joshua M |
| author_sort | Nicholson, Joshua M |
| collection | PubMed |
| description | The promise to understand cancer and develop efficacious therapies by sequencing thousands of cancers has not occurred. Mutations in specific genes termed oncogenes and tumor suppressor genes are extremely heterogeneous amongst the same type of cancer as well as between cancers. They provide little selective advantage to the cancer and in functional tests have yet to be shown to be sufficient for transformation. Here I discuss the karyotyptic theory of cancer and ask if it is time for a new approach to understanding and ultimately treating cancer. |
| format | Online Article Text |
| id | pubmed-3906905 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39069052014-01-31 Will we cure cancer by sequencing thousands of genomes? Nicholson, Joshua M Mol Cytogenet Commentary The promise to understand cancer and develop efficacious therapies by sequencing thousands of cancers has not occurred. Mutations in specific genes termed oncogenes and tumor suppressor genes are extremely heterogeneous amongst the same type of cancer as well as between cancers. They provide little selective advantage to the cancer and in functional tests have yet to be shown to be sufficient for transformation. Here I discuss the karyotyptic theory of cancer and ask if it is time for a new approach to understanding and ultimately treating cancer. BioMed Central 2013-12-13 /pmc/articles/PMC3906905/ /pubmed/24330806 http://dx.doi.org/10.1186/1755-8166-6-57 Text en Copyright © 2013 Nicholson; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Commentary Nicholson, Joshua M Will we cure cancer by sequencing thousands of genomes? |
| title | Will we cure cancer by sequencing thousands of genomes? |
| title_full | Will we cure cancer by sequencing thousands of genomes? |
| title_fullStr | Will we cure cancer by sequencing thousands of genomes? |
| title_full_unstemmed | Will we cure cancer by sequencing thousands of genomes? |
| title_short | Will we cure cancer by sequencing thousands of genomes? |
| title_sort | will we cure cancer by sequencing thousands of genomes? |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906905/ https://www.ncbi.nlm.nih.gov/pubmed/24330806 http://dx.doi.org/10.1186/1755-8166-6-57 |
| work_keys_str_mv | AT nicholsonjoshuam willwecurecancerbysequencingthousandsofgenomes |